Advertisement
MREO vs RARE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Buy and RARE is a StrongBuy.
MREO in upward trend: price may jump up because it broke its lower Bollinger Band on October 12, 2026
MREO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 32 cases where MREO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 62 cases where MREO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MREO as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for MREO just turned positive on November 09, 2026. Looking at past instances where MREO's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
Following a +6.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where MREO advanced for three days, in 184 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
MREO moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MREO crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MREO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MREO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.577) is normal, around the industry mean (3.498). P/E Ratio (-1.415) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (102.041) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MREO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MREO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RARE in upward trend: 10-day moving average broke above 50-day moving average on November 04, 2026
The 10-day moving average for RARE crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 66 cases where RARE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
RARE moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where RARE advanced for three days, in 219 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 152 of 226 cases where RARE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RARE as a result. In 66 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
RARE broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.228) is normal, around the industry mean (3.498). P/E Ratio (-2.647) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.809) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. RARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MREO | RARE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 63 | 64 | |
P/E GROWTH RATING 1..100 | 34 | 10 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RARE's Valuation (15) in the Biotechnology industry is somewhat better than the same rating for MREO (61) in the null industry. This means that RARE’s stock grew somewhat faster than MREO’s over the last 12 months.
RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MREO (100) in the null industry. This means that RARE’s stock grew similarly to MREO’s over the last 12 months.
MREO's SMR Rating (98) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to RARE’s over the last 12 months.
MREO's Price Growth Rating (63) in the null industry is in the same range as RARE (64) in the Biotechnology industry. This means that MREO’s stock grew similarly to RARE’s over the last 12 months.
RARE's P/E Growth Rating (10) in the Biotechnology industry is in the same range as MREO (34) in the null industry. This means that RARE’s stock grew similarly to MREO’s over the last 12 months.
| MREO | RARE | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 74% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 77% |
| MACD ODDS (%) | 1 day ago 68% | N/A |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 72% |
| Advances ODDS (%) | 4 days ago 81% | 9 days ago 78% |
| Declines ODDS (%) | 18 days ago 86% | 7 days ago 80% |
| BollingerBands ODDS (%) | 1 day ago 84% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 67% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MREO’s FA Score shows that 0 FA rating(s) are green while RARE’s FA Score has 2 green FA rating(s).
- MREO’s FA Score: 0 green, 5 red.
- RARE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MREO’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).
- MREO’s TA Score: 5 bullish, 4 bearish.
- RARE’s TA Score: 5 bullish, 3 bearish.
Price Growth
MREO (@Biotechnology) experienced а +0.20% price change this week, while RARE (@Biotechnology) price change was -2.68% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
MREO is expected to report earnings on Mar 31, 2027.
RARE is expected to report earnings on Feb 18, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MREO and
Correlation & Price change
A.I.dvisor indicates that over the last year, MREO has been loosely correlated with RARE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then RARE could also see price increases.
| Ticker / NAME | Correlation To MREO | 1D Price Change % | ||
|---|---|---|---|---|
| MREO | 100% | +2.92% | ||
| RARE - MREO | 58% Loosely correlated | +3.47% | ||
| TRDA - MREO | 40% Loosely correlated | +3.62% | ||
| SYRE - MREO | 38% Loosely correlated | +2.24% | ||
| XNCR - MREO | 38% Loosely correlated | +1.47% | ||
| NRIX - MREO | 38% Loosely correlated | +2.83% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RW | 26.17 | 0.09 | +0.35% |
| Rainwater Equity ETF (RW) | |||
| HYGV | 38.54 | 0.07 | +0.19% |
| Northern Trust High Yield Value-Scored Bond ETF (HYGV) | |||
| PBTP | 25.60 | -0.01 | -0.04% |
| Invesco 0-5 Yr US TIPS ETF (PBTP) | |||
| RSEE | 37.00 | -0.11 | -0.30% |
| Rareview Systematic Equity ETF (RSEE) | |||
| ELC | 18.11 | -0.20 | -1.09% |
| Entergy Louisiana LLC | |||